An interventional study of Dgital micro-intervention in Drug Use and HIV, sponsored by Yale University. Not yet recruiting at 1 site in Kazakhstan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Yale University · Not applicable, Interventional, and Supportive care
This study is a mixed-methods pilot designed to evaluate the feasibility, acceptability, and appropriateness of a brief digital micro-intervention aimed at reducing stigma-related barriers to pre-exposure prophylaxis (PrEP) engagement among people who use drugs (PWUD) in Kazakhstan. Participants will complete baseline and post-intervention surveys and receive structured informational content via Telegram or WhatsApp over approximately 2-3 weeks. The intervention focuses on addressing anticipated stigma, confidentiality concerns, and misinformation that may prevent PWUD from seeking PrEP services. No clinical procedures, medication provision, or biological specimen collection are involved.
The proposed study has three aims:
Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive digital micro-intervention modules via Telegram or WhatsApp over approximately 2-3 weeks.
Behavioral: Dgital micro-intervention
Intervention will include 6-10 brief modules delivered asynchronously consisting of text-based content with optional simple visuals. There is no requirement for participant response. Messages will avoid explicit labeling referencing HIV or drug use in preview text and be written using neutral language. Participants are allowed to discontinue receipt at any time.
Mean Score Acceptability of Intervention Measure (AIM)
Acceptability of the intervention will be assessed using the Acceptability of Intervention Measure (AIM). It has 4-items scored on a 5-point Likert scale summed to achieve a total score. Total score range of 0-20. Higher scores indicate more acceptability.
Time frame: Baseline and Post intervention (Week 4)
Mean Score Intervention Appropriateness Measure (IAM)
The Intervention Appropriateness Measure (IAM) is a 4-item, 5-point Likert scale ( 1=Completely Disagree to 5=Completely Agree) used to evaluate the perceived fit, relevance, or compatibility of an intervention or implementation strategy. Total score range 0-20. Higher scores indicate better appropriateness.
Time frame: Baseline and Post intervention (Week 4)
Mean Score Feasibility of Intervention Measure (FIM)
Feasibility of intervention measured using Feasibility of Intervention Measure (FIM)- a 4-item instrument to assess perceived intervention feasibility. Total score 1-5 with higher scores indicating greater feasibility.
Time frame: Baseline and Post intervention (Week 4)
Change in PrEP knowledge
Measured by a structured survey. Total score range 1-10. Higher scores indicate increased knowledge.
Time frame: Baseline and Post intervention (Week 4)
Change in perceived stigma-related barriers
Measured by a structured survey. Total score range 8-40. Higher scores indicate more barriers.
Time frame: Baseline and Post intervention (Week 4)
Change in readiness to seek PrEP
Measured by Likert scale survey items. Total score range 1-5. Higher scores indicate increased readiness.
Time frame: Baseline and Post intervention (Week 4)
Mean number of clicks or links accessed
Mean number of clicks or links accessed among participants that used the intervention
Time frame: Baseline and Post intervention (Week 4)
Mean number of messages delivered
Mean number of confirmed messages delivered
Time frame: Baseline and Post intervention (Week 4)
Plan to share: Yes — De-identified individual-level participant data collected during the study may be shared with other researchers upon reasonable request after publication of the study results. Shared data will include de-identified survey data and study documentation, such as the study protocol and data dictionary. Data will be shared in a manner consistent with institutional policies and participant confidentiality protections.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.